A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
收藏DataCite Commons2026-04-09 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007374/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine the effect of ixazomib maintenance therapy on
progression free survival (PFS) compared with placebo, in participants with NDMM who have had
a major response (complete response [CR], very good partial response [VGPR], or partial
response [PR]) to initial therapy and who have not undergone SCT.
提供机构：
Vivli
创建时间：
2021-08-25
